Source: International Congress 2016 – ILD: from the bench to the bedside
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Cataldo Martucci (Parma, Italy), Cataldo Martucci, Annalisa Murgo, Valentina Bagnacani, Giancarlo Aquino, Mary Fitzgerlad, Hanry Finch, Craig Fox, Chiara Carnini, Riccardo Patacchini, Maurizio Civelli, Gino Villetti. CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat. Eur Respir J 2016; 48: Suppl. 60, 3887

Member's Comments

No comment yet.

Related content which might interest you: The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8 Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Nicotine impairs inflammation-induced airway relaxation in a in vitro murine model of asthma Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 BmTI-A, a serine protease inhibitor, reduces the chronic allergic lung inflammation in a mice model Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Bcl-2 antagonist ABT-737 attenuates corticosteroid-insensitive neutrophilic airway inflammation Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Characterization of an endogenous Th17-cell generation during sensitization in the murine lung Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 LATE-BREAKING ABSTRACT: MUC1 downregulation induces corticosteroid resistance in asthma’s in vitro and in vivo models Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Antioxidant effects of bisphosphonates in smoking- induced lung injury in rat model Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa response Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015